Stifel Financial Has Upped Its V F (VFC) Position; Mirati Therapeutics Has 2.21 Sentiment

April 17, 2018 - By Moses P. Lee

V.F. Corporation (NYSE:VFC) Logo

Stifel Financial Corp increased V F Corp (VFC) stake by 8.29% reported in 2017Q4 SEC filing. Stifel Financial Corp acquired 84,793 shares as V F Corp (VFC)’s stock declined 0.19%. The Stifel Financial Corp holds 1.11M shares with $81.97M value, up from 1.02 million last quarter. V F Corp now has $31.16 billion valuation. The stock increased 0.81% or $0.6299 during the last trading session, reaching $78.5499. About 640,261 shares traded. V.F. Corporation (NYSE:VFC) has risen 34.81% since April 17, 2017 and is uptrending. It has outperformed by 23.26% the S&P500.

Mirati Therapeutics Inc (MRTX) investors sentiment increased to 2.21 in 2017 Q4. It’s up 1.04, from 1.17 in 2017Q3. The ratio increased, as 42 active investment managers increased and opened new equity positions, while 19 trimmed and sold stakes in Mirati Therapeutics Inc. The active investment managers in our database reported: 17.76 million shares, up from 13.25 million shares in 2017Q3. Also, the number of active investment managers holding Mirati Therapeutics Inc in top ten equity positions increased from 1 to 2 for an increase of 1. Sold All: 10 Reduced: 9 Increased: 15 New Position: 27.

Broadfin Capital Llc holds 7.3% of its portfolio in Mirati Therapeutics, Inc. for 2.45 million shares. Venbio Select Advisor Llc owns 4.40 million shares or 5.2% of their US portfolio. Moreover, Ghost Tree Capital Llc has 2.57% invested in the company for 600,000 shares. The Massachusetts-based Cormorant Asset Management Llc has invested 2.35% in the stock. Acuta Capital Partners Llc, a California-based fund reported 155,000 shares.

Analysts await Mirati Therapeutics, Inc. (NASDAQ:MRTX) to report earnings on May, 3. They expect $-0.67 earnings per share, up 8.22% or $0.06 from last year’s $-0.73 per share. After $-0.67 actual earnings per share reported by Mirati Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company has market cap of $923.19 million. The companyÂ’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. It currently has negative earnings. The Company’s clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC.

Since January 1, 0001, it had 0 buys, and 6 selling transactions for $4.24 million activity.

The stock increased 3.07% or $0.95 during the last trading session, reaching $31.9. About 152,163 shares traded. Mirati Therapeutics, Inc. (MRTX) has risen 472.12% since April 17, 2017 and is uptrending. It has outperformed by 460.57% the S&P500.

Among 30 analysts covering V.F. Corp (NYSE:VFC), 14 have Buy rating, 1 Sell and 15 Hold. Therefore 47% are positive. V.F. Corp had 106 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of V.F. Corporation (NYSE:VFC) earned “Neutral” rating by Goldman Sachs on Thursday, February 2. PiperJaffray downgraded the stock to “Neutral” rating in Tuesday, January 3 report. The firm has “Hold” rating given on Thursday, July 20 by Piper Jaffray. Cowen & Co maintained V.F. Corporation (NYSE:VFC) rating on Monday, October 23. Cowen & Co has “Hold” rating and $69.0 target. KeyBanc Capital Markets downgraded the stock to “Sector Weight” rating in Monday, September 25 report. The stock of V.F. Corporation (NYSE:VFC) has “Equal-Weight” rating given on Wednesday, February 22 by Morgan Stanley. The firm has “Hold” rating by BB&T Capital given on Monday, April 25. Piper Jaffray maintained the stock with “Hold” rating in Friday, January 26 report. The rating was maintained by Cowen & Co with “Hold” on Monday, February 5. The stock of V.F. Corporation (NYSE:VFC) earned “Neutral” rating by JP Morgan on Monday, October 24.

Investors sentiment decreased to 1.01 in 2017 Q4. Its down 0.07, from 1.08 in 2017Q3. It turned negative, as 41 investors sold VFC shares while 258 reduced holdings. 106 funds opened positions while 196 raised stakes. 392.21 million shares or 0.79% less from 395.35 million shares in 2017Q3 were reported. Fred Alger Management has 362 shares. Putnam Invs Ltd holds 0% of its portfolio in V.F. Corporation (NYSE:VFC) for 4,680 shares. Schwartz Investment Counsel stated it has 3.36% in V.F. Corporation (NYSE:VFC). Congress Asset Mngmt Company Ma owns 763,659 shares. Cap Counsel Ltd Liability Co New York invested in 0.05% or 8,721 shares. Apg Asset Nv stated it has 481,666 shares or 0.05% of all its holdings. Vigilant Capital Mngmt Limited Co holds 1,075 shares or 0.01% of its portfolio. St James Ltd Liability invested in 4.34% or 507,609 shares. Commerce Natl Bank invested 0.15% of its portfolio in V.F. Corporation (NYSE:VFC). 870 were accumulated by Howe & Rusling Inc. Keybank Association Oh invested 0.01% in V.F. Corporation (NYSE:VFC). Tompkins Financial Corporation has 685 shares for 0.01% of their portfolio. Veritable Ltd Partnership has invested 0.02% in V.F. Corporation (NYSE:VFC). Hallmark Capital Mgmt Inc holds 25,570 shares. Barrett Asset Mgmt owns 266 shares for 0% of their portfolio.

Stifel Financial Corp decreased Powershares Etf Tr Ii (SPLV) stake by 7,558 shares to 276,957 valued at $13.23 million in 2017Q4. It also reduced Leidos Hldgs Inc (NYSE:LDOS) stake by 15,112 shares and now owns 151,355 shares. Magellan Midstream Prtnrs Lp (NYSE:MMP) was reduced too.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Moses P. Lee

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: